Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
Elke Jäger(Krankenhaus Nordwest), Alexander Knuth(National Center for Cancer Care and Research), Yao‐Tseng Chen(Memorial Sloan Kettering Cancer Center), Antje Neumann(Memorial Sloan Kettering Cancer Center), Michael Arand(University of Zurich), Gerd Ritter(Ludwig Cancer Research), Elisabeth Stockert(Memorial Sloan Kettering Cancer Center), Sacha Gnjatic(Mount Sinai Hospital), Lloyd J. Old(Gynecologic Oncology Group), Julia Karbach(Memorial Sloan Kettering Cancer Center), Yasuhiro Nagata(Memorial Sloan Kettering Cancer Center), Eric W. Hoffman(Cornell University), Dirk Jäger(Memorial Sloan Kettering Cancer Center), Julia Rieckenberg(Memorial Sloan Kettering Cancer Center)
Cited by 426
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k